300110 Stock Overview
Produces and sells non-PVC soft bag infusions in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Huaren Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.26 |
| 52 Week High | CN¥4.32 |
| 52 Week Low | CN¥2.71 |
| Beta | 0.33 |
| 1 Month Change | 12.41% |
| 3 Month Change | 5.50% |
| 1 Year Change | -1.21% |
| 3 Year Change | -12.13% |
| 5 Year Change | -17.47% |
| Change since IPO | -32.49% |
Recent News & Updates
Some Investors May Be Willing To Look Past Huaren Pharmaceutical's (SZSE:300110) Soft Earnings
Nov 04
Shareholder Returns
| 300110 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 2.8% | 3.8% | 0.1% |
| 1Y | -1.2% | 10.9% | 10.1% |
Return vs Industry: 300110 underperformed the CN Pharmaceuticals industry which returned 10.9% over the past year.
Return vs Market: 300110 underperformed the CN Market which returned 10.1% over the past year.
Price Volatility
| 300110 volatility | |
|---|---|
| 300110 Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 300110 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300110's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 2,681 | Liang Hong | www.qdhuaren.com |
Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium, chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. The company also provides therapeutic infusion products for blood volume expansion, hemostasis, nervous and circulatory systems, anti-infection, anti-hepatitis, hepatitis adjuvant, anti-tumor, and sugar metabolism; and medical instruments, such as disposable incision retractors, disposable cannula puncture devices disposable specimen extractors, abdominal suction tubes, incision retractor protectors, iodine protective caps, slip pads, respiratory oscillation expectoration machines, protective mask cup types, protective and foldable disposable masks, and medical protective masks.
Huaren Pharmaceutical Co., Ltd. Fundamentals Summary
| 300110 fundamental statistics | |
|---|---|
| Market cap | CN¥3.79b |
| Earnings (TTM) | -CN¥1.37b |
| Revenue (TTM) | CN¥1.35b |
Is 300110 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300110 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.35b |
| Cost of Revenue | CN¥876.83m |
| Gross Profit | CN¥476.33m |
| Other Expenses | CN¥1.84b |
| Earnings | -CN¥1.37b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16 |
| Gross Margin | 35.20% |
| Net Profit Margin | -101.13% |
| Debt/Equity Ratio | 115.1% |
How did 300110 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/03 15:56 |
| End of Day Share Price | 2025/06/03 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Huaren Pharmaceutical Co., Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jun Liu | Changjiang Securities Co. LTD. |
| Jie Yao | Everbright Securities Co. Ltd. |
| Jianjian Li | Founder Securities Co., Ltd. |